|Mr. Daniel Anton de Boer||CEO & Member of Management Board||N/A||N/A||1983|
|Mr. Gerard Platenburg||Co-Founder & Chief Innovation Officer||N/A||N/A||1964|
|Ms. Smital Shah M.B.A.||Chief Bus. & Financial Officer||N/A||N/A||1976|
|Dr. Naveed K. Shams||Chief Scientific Officer||N/A||N/A||1957|
|Ms. Sarah Cue Kiely||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Sheila Sponselee||VP of HR||N/A||N/A||N/A|
|Mr. Bart Klein||Sr. VP of Intellectual Property||N/A||N/A||N/A|
|Ms. Bianca Matthee||Head of Manufacturing and Pharmaceutics||N/A||N/A||N/A|
|Mr. Aniz Girach||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Tiffany Burt||Head of Commercial & VP||N/A||N/A||N/A|
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
ProQR Therapeutics N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.